Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients
- Registration Number
- NCT05224492
- Lead Sponsor
- Sunshine Specialty Health Care
- Brief Summary
Assess the effects of Sulforaphane supplementation in HIV patients that have achieved viral suppression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- HIV patients on active treatment who have a suppressed viral load and have been virally suppressed for 6 months or more.
- BMI increase of 10% or more since initiation of HIV treatment over a year period.
- BMI equal to or greater than 30.
- 18-85 years of age.
Read More
Exclusion Criteria
- Cancer
- Pregnancy or breastfeeding
- Intolerance to cruciferous vegetables
- Intolerance to sulforaphane
- Gluten Intolerance
- Creatinine > 1.3 mg/dL
- GFR < 60
- AST or ALT > 1.5 times upper limit of normal.
- White cell count < 2000 cells per ml.
- Hemoglobin < 10.5 g/dL.
- Platelet count < 140,000 per ml.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Group Placebo - Sulforaphane Group Sulforaphane -
- Primary Outcome Measures
Name Time Method Lipids 4 months Triglycerides, Cholesterol
Inflammatory Markers 4 months CRP
- Secondary Outcome Measures
Name Time Method